ORIGINAL ARTICLE

Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection

Kazumoto Murata,1 Mai Asano,1,2 Akihiro Matsumoto,3 Masaya Sugiyama,1 Nao Nishida,1 Eiji Tanaka,3 Taisuke Inoue,4 Minoru Sakamoto,4 Nobuyuki Enomoto,4 Takayoshi Shirasaki,5 Masao Honda,5 Shuichi Kaneko,5 Hiroyuki Gatanaga,6 Shinichi Oka,6 Yuki I Kawamura,7 Taeko Dohi,7 Yasutaka Shuno,8 Hideaki Yano,8 Masashi Mizokami1,2

ABSTRACT

Objective The clinical significance of polymorphisms in the interleukin-28B gene encoding interferon (IFN)-λ3, which has antiviral effects, is known in chronic HCV but not in HBV infection. Thus, we measured IFN-λ3 levels in patients with HBV and investigated its clinical significance and association with nucleos(t)ide (NUC) analogue administration.

Design Serum IFN-λ3 level was measured in 254 patients with HBV with varying clinical conditions using our own high sensitivity method. The resulting values were compared with various clinical variables. In addition, cell lines originating from various organs were cultured with NUCs, and the production of IFN-λ3 was evaluated.

Results Higher serum IFN-λ3 levels were detected in the patients treated with nucleotide analogues (adefovir or tenofovir) compared with those treated with nucleoside analogues (lamivudine or entecavir). There were no other differences in the clinical background between the two groups. A rise in the serum IFN-λ3 levels was observed during additional administration of nucleotide analogues. In vitro experiments showed that the nucleotide analogues directly and dose-dependently induced IFN-λ3 production only in colon cancer cells. Furthermore, the supernatant from cultured adefovir-treated colon cancer cells significantly induced IFN-stimulated genes (ISGs) and inhibited hepatitis B surface antigen (HBsAg) production in hepatoma cells, as compared with the supernatant from entecavir-treated cells.

Conclusions We discovered that the nucleotide analogues show an additional pharmacological effect by inducing IFN-λ3 production, which further induces ISGs and results in a reduction of HBsAg production. These findings provide novel insights for HBV treatment and suggest IFN-λ3 induction as a possible target.

INTRODUCTION

Over 240 million people are infected with HBV worldwide. HBV is a life-threatening infectious virus involving a risk of cirrhosis and hepatocellular carcinoma (HCC), and it is responsible for more than 786 000 deaths annually.1 2 Nucleos(t)ide analogues (NUCs) safely control the HBV replication and thus reduce the risk of HCC development3 and HBV-associated mortality.4 However, the effects of NUCs on serum hepatitis B surface antigen (HBsAg) levels are limited because NUCs have no direct effect on covalently closed circular

Significance of this study

What is already known on this subject?

▸ Both nucleoside and nucleotide analogues inhibit the HBV reverse transcriptase function; however, their other effects are unknown.

▸ Clinical importance of the interleukin-28B gene, which encodes interferon (IFN)-λ3, has been established in HCV infection but not HBV infection.

What are the new findings?

▸ Serum IFN-λ3 levels increased after administration of nucleotide analogues in both patients with HBV and HIV, suggesting that the nucleotide analogues themselves were considered to induce IFN-λ3.

▸ Among the various tested cell lines that potentially produce IFN-λ3, the nucleotide analogues were found to directly induce IFN-λ3 at the mRNA and protein levels only in colon cancer cells.

▸ The supernatant (containing induced IFN-λ3) from adefovir-treated colon cancer cells robustly induced IFN-stimulated genes (ISGs) and suppressed hepatitis B surface antigen production in hepatoma cell lines.

How might it impact on clinical practice in the foreseeable future?

▸ We discovered a novel additional pharmacological effect of nucleotide analogues involving the induction of IFN-λ3 production in GI cells, which in turn induced ISGs in hepatic cells. The discovery of this mechanism is a new advancement for HBV treatment, suggesting the possibility of developing an anti-HBV treatment targeting IFN-λ3 induction.
DNA, which acts as a viral template. Therefore, long-term treatment is necessary for HBsAg loss, which is correlated with low incidence of HCC. On the other hand, treatment with interferon (IFN)-α is a finite course that has direct anti-HBV and immunomodulatory effects. However, only limited cases have been reported that achieved HBsAg loss. Consequently, the inability to completely eliminate HBV is a problem associated with current treatments. Thus, new treatment strategies are desired.

Using a genome-wide association study (GWAS), we and other researchers have identified single-nucleotide polymorphisms in the promoter region of the interleukin-28B gene (IL-28B) to be strongly associated with the effect of hepatitis C combination therapy with pegylated IFN-α (PEG-IFN)/ribavirin. On the other hand, although there have been a number of reports on the association between hepatitis B and IL-28B gene polymorphisms, they have not led to consistent opinions. These studies are not easily comparable because of heterogeneous patient backgrounds, such as different HBV genotypes or different treatment regimens. We hypothesised, however, that the inconsistent results might have been mainly due to investigation performed at the gene level because gene expression is generally affected by transcriptional or post-transcriptional modifications. Thus, in this study we analysed the IL-28B protein levels in patients with HBV. We focused specifically on IFN-λ3 because it was IL-28B that was identified in the hepatitis C GWAS, and not IL-29 (IFN-λ1) or IL-28A (IFN-λ2). Furthermore, IFN-λ3 induces IFN-stimulated genes (ISGs) more strongly and has a more pronounced antiviral effect than IFN-λ1 or IFN-λ2.

At present, there exist three independent reports on serum IFN-λ levels. However, the data have not led to a unified conclusion because different assays were used for measurements and there were only few subjects. Therefore, we developed our own IFN-λ3 measurement system, which detects IFN-λ3 in a highly sensitive and specific manner. Additionally, it exhibits clear linearity in the 1–100 pg/mL range, which corresponds to serum IFN-λ3 concentrations.

In this study, we measured serum IFN-λ3 levels in patients with HBV using this assay and investigated the clinical significance of IFN-λ3 and its association with NUC administration.

**MATERIALS AND METHODS**

**Patients**

Serum and DNA samples were obtained from 254 consecutive Japanese patients with HBV who visited the National Center for Global Health and Medicine, Kohnozai Hospital, Yamanashi University Hospital, or Shinshu University Hospital between January 2011 and March 2013. All patients who agreed to participate in this study were included, and all were negative for HCV. For serial measurements of IFN-λ3, frozen sera from our cohort of patients with HBV were used. A separate series of sera from patients with HIV infection, receiving antiretroviral therapy with or without tenofovir disoproxil fumarate (TDF), was obtained from the AIDS Clinical Center, National Center for Global Health and Medicine. All serum and DNA samples were stored at −80°C until use.

The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Written informed consent was obtained from all patients.

**IL28B genotyping, and measurement of HBsAg and HBV DNA**

See the online supplementary materials and methods.

**Measurement of IFN-λ1, IFN-λ2, IFN-λ3, IFN-α and IFN-β**

IFN-λ3 level was measured in the serum and supernatants using a chemiluminescence enzyme immunoassay developed in-house, as previously reported. See the online supplementary materials and methods for IFN-λ1, IFN-λ2, IFN-α and IFN-β.

**Cell culture**

Various cell lines, originating from lymphocytes (Raji), skin (HKA-1 and HSC-5), lungs (A-549, EBC-1 and RERF-LC-sq1), stomach (AZ-521), liver (HepG2, Huh7 and PLC/PRF/5) and colon (WiDr and HT-29), were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Wako Pure Chemicals, Osaka, Japan) supplemented with 10% fetal calf serum or in Roswell Park Memorial Institute medium (RPMI) (Life Technologies, Grand Island, New York, USA). HT-29 cells were purchased from the American Type Culture Collection (Manassas, Virginia, USA), and the rest were purchased from the Japanese Cancer Research Resources Bank (Osaka, Japan). Peripheral blood mononuclear cells (PBMCs) from healthy volunteers were separated by density-gradient centrifugation, and PXB cells (Phoenix Bio, Hiroshima, Japan) were obtained from chimeraile mice with humanised livers. Adherent and suspension cells were seeded at a density of 1×10⁵ cells and 1×10⁶ cells per well, respectively. Each cell line was incubated with lamivudine (LAM, 50 μM), adefovir pivoxil (ADV, 2.5 μM), entecavir (ETV, 0.25 μM) or TDF (50 μM) for 48 hours. LAM was purchased from Sigma-Aldrich (St Louis, Missouri, USA) and the other NUCs were purchased from Adooq Bioscience (Irvine, California, USA). Each molar NUC concentration was determined based on the regular clinical oral dose used for patients with HBV Dimethyl sulfoxide (DMSO, 0.1%) was used as a negative control. IFN-α (100 U/mL; Otsuka Pharmaceutical, Tokyo, Japan), with or without 30 μg/mL poly I:C (Imgenex, San Diego, California, USA), a toll-like receptor 3 (TLR3) agonist, or 5 μg/mL R-837 (Imgenex), a TLR7 agonist, was used as a positive control. To determine the dose dependency, we used 1:3 dilutions of each NUC and positive controls. To evaluate the effect of IFN-α on IFN-λ3 production, WiDr or HT-29 cells were treated with each NUC with or without IFN-α (100 U/mL) for 48 hours. IFN-α (10 U/mL, 100 U/mL, 1000 U/mL) was used as a positive control.

**Immunohistochemistry**

WiDr cells were cultured in a chamber slide (Nunc, Rochester, New York, USA) with 0.1% DMSO, 50 μM LAM, 2.5 μM ADV, 0.25 μM ETV or 50 μM TDF under the above conditions for 48 hours. After drying, the cells were fixed with 4% paraformaldehyde, and endogenous peroxidase was blocked using 0.3% H2O2. An avidin-biotin complex kit was obtained from Vector Laboratories (Burlingame, California, USA). After blocking the slides with horse serum, a primary mouse anti-IFN-λ3 antibody (TA2664; 1:100), originally generated in our laboratory, was applied and reacted overnight at 4°C. For colour development, 0.05% (w/v) 3,3’-diamino-benzidine tetrahydrochloride (Sigma-Aldrich) was used. The cells were counterstained with haematoxylin.

**Quantitative PCR for IFN-λ3**

See the online supplementary materials and methods.

**Analysis of ISGs**

To analyse the expression of ISGs, HepG2 and Huh7 cells (1×10⁵ cells per well) were incubated with a medium containing

---


Gut: first published as 10.1136/gutjnl-2016-312653 on 27 October 2016. Downloaded from http://gut.bmj.com/ on September 15, 2023 by guest. Protected by copyright.
Inhibition of HBsAg production in PLC/PRF/5 cells

To analyse the effect of IFN-λ3 on HBsAg levels, PLC/PRF/5 cells (5×10⁴ cells per well) were treated with various concentrations of recombinant IFN-λ3 (R&D Systems, Minneapolis, Minnesota, USA), with DMSO control medium, and with the supernatants of ADV-treated and ETV-treated WiDr cells for 3 days. HBsAg in the cell supernatants was quantified.

Statistical analyses

Mann-Whitney U test and Kruskal-Wallis test were used to compare continuous data between patient subgroups. Pearson’s χ² test and Fisher’s exact test were used to compare non-parametrical categorical data. Pearson’s product-moment correlation was used to evaluate the relationship between two variables. All tests were performed using the IBM SPSS Statistics Desktop for Japan, V19.0 (IBM Japan, Tokyo, Japan) and p values <0.05 were considered statistically significant.

RESULTS

Patients’ background

Serum and DNA samples were obtained from patients with HBV infection, including asymptomatic carriers (ASCs, n=83) and patients with chronic hepatitis (CH, n=103), liver cirrhosis (LC, n=25) and HCC (n=43). HCC was observed in 10 patients with CH and 33 patients with LC. NUCs were administered to 80 CH, 22 LC and 40 HCC cases. The NUC treatments were as follows: LAM (n=6), ETV (n=111), TDF (n=1), LAM+ADV (n=22), ETV+ADV (n=1) and multiple NUCs (n=1). Patients who were treated with IFN-α at the time of sampling were excluded. The serum albumin, cholinesterase, total cholesterol, HBsAg levels and platelet counts were lower in the patients with advanced liver disease. An advanced age and the male sex were correlated with advanced liver disease (table 1).

We compared IL-28B gene polymorphisms among the patients at different clinical stages and found that TT, the major homozygous genotype of IL-28B, was less prevalent in patients at more advanced stages of the disease (80.7%, 73.8%, 52.0% and 79.1% in the ASCs and patients with CH, LC and HCC, respectively, p=0.031).

Serum IFN-λ3 levels in patients with HBV

We compared serum IFN-λ3 levels in the patients with different IL-28B genotypes (TT vs non-TT; figure 1A) and hepatitis B e antigen statuses (positive vs negative; figure 1B) but did not find differences between the respective groups. We also investigated a correlation between the serum IFN-λ3 levels and the disease

### Table 1 Patient characteristics (n=254)

<table>
<thead>
<tr>
<th></th>
<th>ASC (n=83)</th>
<th>CH (n=103)</th>
<th>LC (n=25)</th>
<th>HCC (n=43)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>103</td>
<td>82</td>
<td>23</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>Age (years)*</td>
<td>50 (26–83)</td>
<td>49 (19–85)</td>
<td>62 (35–74)</td>
<td>63 (41–86)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sex (M:F)</td>
<td>36:47</td>
<td>63:40</td>
<td>18:7</td>
<td>31:12</td>
<td>0.002</td>
</tr>
<tr>
<td>HBeAg+</td>
<td>2 (2.4%)</td>
<td>31 (30.1%)</td>
<td>8 (32.0%)</td>
<td>9 (20.9%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Alb (g/dL)*</td>
<td>4.5 (3.2–5.2)</td>
<td>4.4 (3.3–5.3)</td>
<td>4.4 (2.1–4.4)</td>
<td>4.2 (2.1–5.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>AST (U/L)*</td>
<td>21 (11–87)</td>
<td>22 (13–238)</td>
<td>24 (14–153)</td>
<td>25 (14–99)</td>
<td>0.006</td>
</tr>
<tr>
<td>ALT (U/L)*</td>
<td>18 (9–93)</td>
<td>20 (8–375)</td>
<td>18 (11–110)</td>
<td>19 (8–57)</td>
<td>NS</td>
</tr>
<tr>
<td>ChE (U/L)*</td>
<td>338 (189–848)</td>
<td>314 (127–578)</td>
<td>278 (74–382)</td>
<td>265 (38–443)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>T-cho (mg/dL)*</td>
<td>170 (101–289)</td>
<td>186 (94–315)</td>
<td>171 (101–48)</td>
<td>169 (85–257)</td>
<td>0.013</td>
</tr>
<tr>
<td>BUN (mg/dL)*</td>
<td>17 (12–70)</td>
<td>18 (13–59)</td>
<td>14 (11–61)</td>
<td>16 (9–91)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cre (mg/dL)*</td>
<td>0.65 (0.36–3.65)</td>
<td>0.77 (0.37–6.2)</td>
<td>0.78 (0.43–1.33)</td>
<td>0.77 (0.45–1.99)</td>
<td>0.002</td>
</tr>
<tr>
<td>WBC (x10³/μL)*</td>
<td>50 (28–150)</td>
<td>48 (21–93)</td>
<td>44 (28–94)</td>
<td>42 (15–85)</td>
<td>NS</td>
</tr>
<tr>
<td>Hb (g/dL)*</td>
<td>13.8 (9.2–16.7)</td>
<td>14.3 (9.9–18.0)</td>
<td>14.0 (8.6–17.4)</td>
<td>13.4 (8.7–16.4)</td>
<td>NS</td>
</tr>
<tr>
<td>PIt (x10³/μL)*</td>
<td>19.7 (9.5–49.9)</td>
<td>17.8 (6.3–32.2)</td>
<td>10.7 (4.7–20.3)</td>
<td>11.7 (2.5–29.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>AFP (ng/mL)*</td>
<td>2.5 (0.7–80.1)</td>
<td>2.5 (0.8–417.4)</td>
<td>2.6 (1.5–23.0)</td>
<td>3.0 (0.8–4834)</td>
<td>NS</td>
</tr>
<tr>
<td>HBsAg (IU/mL)*</td>
<td>572 (1.1–64 510)</td>
<td>1130 (1–50 460)</td>
<td>823 (1–4326)</td>
<td>199 (1–3212)</td>
<td>0.001</td>
</tr>
<tr>
<td>HBV DNA*</td>
<td>3.2 (UD–9.0)</td>
<td>2.1 (UD–6.9)</td>
<td>2.1 (UD–7.3)</td>
<td>UD (UD–6.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>(log copies/mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-28B (TT:non-TT)</td>
<td>67:16</td>
<td>76:27</td>
<td>13:12</td>
<td>34:9</td>
<td>0.031</td>
</tr>
<tr>
<td>No treatment</td>
<td>83</td>
<td>23</td>
<td>3</td>
<td>3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Treatment with NUCs</td>
<td>0</td>
<td>80</td>
<td>22</td>
<td>40</td>
<td></td>
</tr>
</tbody>
</table>

*Data are presented as median (range).
†Data are presented as a positive number (%).

AFP, α-fetoprotein; Alb, albumin; ALT, alanine aminotransferase; ASC, asymptomatic carrier; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CH, chronic hepatitis; ChE, cholinesterase; Cre, creatine; HB, haemoglobin; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; LC, liver cirrhosis; ND, not determined; NS, non-significant; NUC, nucleos(t)ide analogue; PIt, platelet count; T-cho, total cholesterol; TT, major homozygous genotype of IL-28B; UD, under detection threshold; WBC, white blood cell.
progression. In all treatment-naïve patients, the serum IFN-λ3 levels were no greater than 20 pg/mL, and there was no difference depending on the clinical condition (n=112; figure 1C). The serum IFN-λ3 levels showed a weak negative correlation with age (correlation coefficient (CC)=−0.205) and weak positive correlations with HBsAg (CC=0.278) and HBV DNA (CC=0.215) levels; however, no correlation was observed with the other test values (see online supplementary table S1). No significant changes in the serum IFN-λ3 levels were observed during the course of acute hepatitis B (see online supplementary figure S1A and B). Taken together, these results suggest that serum IFN-λ3 levels do not reflect the pathogenesis of HBV. However, compared with the treatment-naïve patients (figure 1C), higher serum IFN-λ3 levels were found in the patients undergoing NUC treatment (figure 1D).

Serum IFN-λ3 levels depending on NUC type
We compared serum IFN-λ3 levels among the patients undergoing treatment with the different types of NUCs (n=142). Higher serum IFN-λ3 levels were found in the patients treated with the nucleotide analogues (ADV or TDF; 27.2 pg/mL (range: 3.4–113.2), n=25) compared with those treated with the nucleoside analogues (LAM or ETV; 1.4 pg/mL (range: 0.1–32.5), n=117) (figure 1E). These associations were not found in serum levels of IFN-λ1 or IFN-λ2 (see online supplementary figure S2). The clinical backgrounds of the patients in the two groups revealed no differences, except the serum IFN-λ3 levels and the duration of NUC treatment (table 2). However, there was no correlation between the NUC treatment duration and serum IFN-λ3 levels (see online supplementary figure S3A and B).

Changes in serum IFN-λ3 values before and during NUC treatment
To confirm the association between nucleotide analogue treatment and IFN-λ3, we measured serum IFN-λ3 levels in serial samples obtained before and during NUC treatment. Serial serum samples were conserved for 20 patients treated with LAM and/or ETV, 19 cases treated with an ADV-containing regimen, one case treated with TDF alone, and one case treated with multiple NUCs as described below. No elevation of the serum IFN-λ3 levels was observed during the treatment with LAM and/or ETV (figure 2A, C). However, the serum IFN-λ3 levels rose with the start of ADV (figure 2B, D) or TDF (figure 2E) treatment. The data for the patient treated with various different NUCs are shown in figure 2F. His serum

Figure 1  Serum interferon (IFN)-λ3 levels in patients with HBV (n=254). Serum IFN-λ3 levels in patients with different IL-28B genotypes (A) and HBeAg positivity statuses (B). Serum IFN-λ3 levels and the disease statuses (C) in treatment-naïve patients (n=112) and (D) in patients treated with nucleos(t)ide analogues (NUCs) (n=142). (E) Serum IFN-λ3 levels in patients treated with different NUCs (n=142). ADV, adefovir pivoxil; ASC, asymptomatic carrier; CH, chronic hepatitis; ETV, entecavir; HBeAg, hepatitis B e antigen; HCC, hepatocellular carcinoma; LAM, lamivudine; LC, liver cirrhosis; TDF, tenofovir disoproxil fumarate; TT, major homozygous genotype of IL-28B.
IFN-α level was high during the treatment with LAM+ADV when he first visited our hospital. However, after the ADV administration was stopped due to the onset of renal damage, his IFN-α level suddenly declined and remained low during the treatment with LAM+ETV. After switching to TDF due to the appearance of ETV-resistant viral clones, his serum IFN-α level suddenly declined and remained low during the TDF dose was reduced.

Next, we investigated whether this phenomenon would also be observed in patients with HIV treated with NUCs. As expected, the serum IFN-α levels rose after initiating treatment with TDF, but no such elevation was observed in the patients treated without TDF (figure 2G, see online supplementary figure S4A–C). These observations strongly suggested that the nucleotide analogues are themselves responsible for the induction of IFN-α, regardless of the presence of HBV or HIV infection.

IFN-α level was induced by nucleotide analogues in a number of cell types

We sought to confirm that the nucleotide analogues induce IFN-α production in vitro. In this experiment, we used cell lines derived from organs previously reported to produce IFN-α (lymphocytes, skin, lungs, stomach and liver). As primary cells, we used PBMCs sampled from healthy adults and hepatocytes sampled from chimpanzee with humanised livers. IFN-α was produced in at least one of the three positive controls (see Materials and methods) for all cells tested, suggesting that all the cells used had the potential to produce IFN-α. However, none of the NUCs induced IFN-α in any of the cells tested (figure 3). IFN-α was not induced in HepG2 or Huh7 cells relative to any of the positive controls (see online supplementary figure S5).

### Nucleotide analogues induce IFN-α only in colon cancer cell lines

Next, we used colon cancer cell lines because NUCs are administered orally and thus enter the GI tract. IFN-α induction was detected in the supernatants from WiDr and HT-29 cells treated with the nucleotide analogues (figure 4A). On the other hand, the results obtained with the nucleoside analogues were comparable to those obtained with DMSO, which was the negative control. Similar tendencies were observed in IFN-λ1 and IFN-λ2 levels in the supernatant (see online supplementary figure S6). ADV and TDF induced IFN-α in a dose-dependent manner (figure 4B). These results were similar to those obtained with the patients' sera. Furthermore, IL-28B mRNA was significantly upregulated by the nucleotide analogue treatments in both WiDr and HT-29 cells (figure 4C). Immunohistochemistry showed clear positive staining for IFN-λ1 in the cytoplasm, and a higher frequency of IFN-λ3-positive cells was found among the WiDr cells treated with the nucleotide analogues compared with those treated with DMSO or the nucleoside analogues (figure 4D). When no primary antibody was used, no positive staining for IFN-λ3 was observed. As indicated in figure 4A, IFN-α induced IFN-λ3 in the colon cancer cell lines, and the possibility that the NUCs indirectly induced IFN-λ3 via IFN-α or IFN-β induction could not be ruled out. Thus, in order to rule this out, we measured IFN-α and IFN-β in the same supernatant shown in figure 4A. However, the data showed that none of the NUCs induced IFN-α or IFN-β (see online supplementary figure S7A and B, respectively). Taken together, these results suggest that ADV and TDF directly induced IFN-λ3 in the colon cancer cell lines.

### Induction of ISGs in hepatoma cells by the supernatant of ADV-treated colon cancer cells

We evaluated whether the supernatants obtained from the cultures of the ADV-treated or ETV-treated WiDr cells could induce ISGs in HepG2 or Huh7 cells. Unlike the DMSO control medium and the supernatants from the ETV-treated cells, the supernatant from the WiDr cells treated with ADV for 48 hours robustly upregulated both MX1 (figure 5A) and OAS2 (figure 5B), which peaked at 12 hours in both HepG2 and Huh7 cells.

### Reduction of HBsAg production in PLC/PRF/5 cells by recombinant IFN-α and the supernatant from ADV-treated colon cancer cells

We evaluated whether recombinant IFN-α and IFN-λ3 induced by ADV would inhibit the HBsAg production in PLC/PRF/5 cells, which constitutively produce HBsAg, but not HBV DNA. Recombinant IFN-λ3 dose-dependently inhibited HBsAg production in PLC/PRF/5 cells (figure 5C) and, in particular, significantly decreased HBsAg production at a concentration of 100 pg/ml, which corresponds to the serum IFN-λ3 level in the patients treated with the nucleotide analogues. Furthermore, the supernatant from the WiDr cells treated with ADV for 48 hours significantly inhibited HBsAg production in PLC/PRF/5 cells, as compared with the DMSO control medium or the supernatants.

---

**Table 2** Clinical backgrounds by different NUCs treatment (n=142)

<table>
<thead>
<tr>
<th></th>
<th>LAM and/or ETV</th>
<th>ADV or TDF</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>117</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Age (years)*</td>
<td>59 (31–86)</td>
<td>62 (37–80)</td>
<td>NS</td>
</tr>
<tr>
<td>Sex</td>
<td>78:39</td>
<td>14:11</td>
<td>NS</td>
</tr>
<tr>
<td>HBV genotype (A:B:C:D:ND)</td>
<td>2:15:92:0:8</td>
<td>0:2:21:0:2</td>
<td>NS</td>
</tr>
<tr>
<td>Alb (g/dl)*</td>
<td>4.4 (2.1–5.1)</td>
<td>4.4 (3.3–5.3)</td>
<td>NS</td>
</tr>
<tr>
<td>AST (U/L)*</td>
<td>22 (13–23)</td>
<td>21 (16–24)</td>
<td>NS</td>
</tr>
<tr>
<td>ALT (U/L)*</td>
<td>19 (8–37)</td>
<td>18 (8–54)</td>
<td>NS</td>
</tr>
<tr>
<td>Cholesterol (mg/dl)*</td>
<td>296 (38–578)</td>
<td>279 (151–443)</td>
<td>NS</td>
</tr>
<tr>
<td>T-cho (mg/dl)*</td>
<td>179 (85–315)</td>
<td>158 (113–226)</td>
<td>NS</td>
</tr>
<tr>
<td>BUN (mg/dl)*</td>
<td>14 (6–39)</td>
<td>17 (1–25)</td>
<td>NS</td>
</tr>
<tr>
<td>Cre (mg/dl)*</td>
<td>0.77 (0.37–2.41)</td>
<td>0.79 (0.47–1.99)</td>
<td>NS</td>
</tr>
<tr>
<td>Platelet (×10^4/μl)*</td>
<td>15.6 (2.5–26.3)</td>
<td>16.4 (8.1–28.7)</td>
<td>NS</td>
</tr>
<tr>
<td>AFP (ng/ml)*</td>
<td>2.5 (0.8–483)</td>
<td>2.1 (0.8–5.6)</td>
<td>NS</td>
</tr>
<tr>
<td>HBsAg (IU/ml)*</td>
<td>826 (1–470)</td>
<td>464 (1–8150)</td>
<td>NS</td>
</tr>
<tr>
<td>HBeAg t</td>
<td>34 (29.1%)</td>
<td>5 (20.0%)</td>
<td>NS</td>
</tr>
<tr>
<td>HBV DNA (log copies/ml)*</td>
<td>UD (UD–8.4)</td>
<td>UD (UD–3.7)</td>
<td>NS</td>
</tr>
<tr>
<td>IL-28B (TT:non-TT)</td>
<td>90:27</td>
<td>15:10</td>
<td>NS</td>
</tr>
<tr>
<td>Cholt/C</td>
<td>72:45</td>
<td>17:8</td>
<td>NS</td>
</tr>
<tr>
<td>Hcrt</td>
<td>34 (29.1%)</td>
<td>6 (24.0%)</td>
<td>NS</td>
</tr>
<tr>
<td>Duration of NUC treatment (months)</td>
<td>37 (1–135)</td>
<td>92 (17–148)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Serum IFN-α (pg/ml)*</td>
<td>1.4 (0.1–32.5)</td>
<td>27.2 (3.4–113.2)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*Data are presented as the median (range).
†Data are presented as a positive number (%).
ADV, adefovir pivoxil; AFP, α-fetoprotein; Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CH, chronic hepatitis; ChE, cholinesterase; Cre, creatinine; ETV, entecavir; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; IFN, interferon; IL-28B, interleukin 28B; LAM, lamivudine; LC, liver cirrhosis; ND, not determined; NS, non-significant; NUC, nucleos(t)ide analogue; Plt, platelet count; T-cho, total cholesterol; TDF, tenofovir disoproxil fumarate; Tt, major homozygous genotype of IL-28B; UD, under detection threshold.
from the WiDr cells treated with ETV (Figure 5D). These reductions in HBsAg production are unlikely to be caused by cell death because neither recombinant IFN-λ3 nor the supernatant affected the cell viability as measured by the MTT assay (see online supplementary figure S8A and B).

**DISCUSSION**

In order to elucidate the clinical significance of IFN-λ3 for hepatitis B, we measured serum IFN-λ3 levels in patients with HBV with varying clinical conditions. We discovered that serum IFN-λ3 was upregulated by nucleotide analogue administration. In cell culture experiments, we found that the nucleotide analogues directly induced IFN-λ3 in colon cancer cell lines. Furthermore, the induced IFN-λ3 in turn induced ISGs in hepatoma cells and inhibited HBsAg production. Based on these results, we conclude that the nucleotide analogues show a novel additional pharmacological effect of inducing IFN-λ3.

NUCs target only the action of reverse transcriptase, which transcribes the pregenomic RNA to HBV DNA, and their other effects are unknown. The predicted time of the HBsAg loss during NUC administration depends on the NUC type, with TDF estimated to have the shortest time. These differences among the NUCs have been explained by their different potentials in inhibition of reverse transcriptase. Meanwhile, it has been reported that TDF prevents the simian immunodeficiency virus infection, and that no incidental acute HBV infections were found in patients with HIV during the course of TDF treatment, although the prevention was not complete when using LAM. These clinical phenomena could be explained by the novel additional effect of the nucleotide analogues in inducing IFN-λ3 and consequently inducing ISGs, as shown in the current study.

IFN-λ3, also known as type III IFNs, have different receptors compared with type I IFNs (IFN-α and IFN-β). However, the two types of IFNs use similar intracellular signalling pathways.
and have similar antiviral activity. Although it has not been completely explained why hosts require IFNs with such similar functions, one of the characteristic features of type III IFNs is organ-specific expression of their receptors. Receptors for type I IFNs exist ubiquitously, whereas those for type III IFNs are largely restricted to cells of epithelial origin, excluding dendritic cells. From this perspective, there is a distinct possibility that type III IFNs contribute to mucosal immunity as a first line of defence against viral invasion. The level of ISG expression induced by an IFN-λ is correlated with the level of type III IFN receptor expression, with the GI tract being an organ with one of the strongest reactions to IFN-λ. In fact, protection from intestinal rotavirus infection was severely impaired in mice lacking a functional type III IFN receptor, and exogenous IFN-λ administration ameliorated murine rotavirus and norovirus infections, even in the absence of adaptive immunity. Furthermore, rotavirus infection has been observed to induce IFN-λ in intestinal cells. This evidence supports the possibility that the nucleotide analogues induce IFN-λ3 in GI cells, as observed in this study. The precise mechanisms of IFN-λ3 induction by nucleotide analogues in the GI tracts are unknown. However, pattern-recognition receptors might recognise nucleotide analogues as pathogen-associated molecular patterns and induce IFN-λ3 as the first line of defence.

This phenomenon of colon IFN-λ3 induction by the nucleotide analogues is clinically important because IFN-λ3 induced in the GI tract reaches the liver via the portal vein. IFN-λ directly inhibits the replication of HBV and dengue virus. IFN-λ also induces ISGs, which contribute to inhibition of viral mRNA translation, as well as to RNA degradation and synthesis. The current study demonstrated that the induced IFN-λ3 further induced ISGs in hepatoma cell lines. Furthermore, recombinant IFN-λ3 and the supernatant from ADV-treated WiDr cells significantly inhibited HBsAg production in PLC/PRF/5 cells. Therefore, IFN-λ3 reaching the liver via the portal vein could exhibit an anti-HBV effect directly or indirectly, via ISGs. Thus, this phenomenon could be an immunomodulatory effect caused by the nucleotide analogues themselves, as noted in a recent review. However, we cannot rule out the possibility that the supernatant from the ADV-treated colon cancer cells may have contained other substances, besides IFN-λ3, contributing to the inhibition of HBsAg production, which deserves further study.

![Figure 3](http://gut.bmj.com/)

**Figure 3** Confirmation of interferon (IFN)-λ3 production induced by nucleos(t)ide analogues. Each cell line, originating from lymphocytes (Raji), skin (HKA-1 and HSC-5), lung (A-549, EBC-1 and RERF-LC-sql), stomach (AZ-521), liver (PLC/PRF/5) and peripheral blood mononuclear cells (PBMCs) or PXB cells were incubated with dimethyl sulfoxide (DMSO, 0.1%), lamivudine (LAM, 50 μM), adefovir pivosil (ADV, 2.5 μM), entecavir (ETV, 0.25 μM) or tenofovir disoproxil fumarate (TDF, 50 μM). After 48 h, the supernatants were subjected to a chemiluminescence enzyme immunoassay for IFN-λ3. IFN-α (100 U/mL), with or without poly I:C (30 μg/mL) or R-837 (5 μg/mL), was used as a positive control. PC, positive controls.
Figure 4  Nucleotide analogues directly induce interferon (IFN)-λ3 in colon cancer cells. (A) Colon cancer cells (WiDr and HT-29) were incubated with dimethyl sulfoxide (DMSO, 0.1%), lamivudine (LAM, 50 μM), adefovir pivoxil (ADV, 2.5 μM), entecavir (ETV, 0.25 μM) or tenofovir disoproxil fumarate (TDF, 50 μM). After 48 hours, the supernatants were subjected to a chemiluminescence enzyme immunoassay for IFN-λ3. IFN-α (100 U/mL), with or without poly I:C (30 μg/mL) or R-837 (5 μg/mL), was used as a positive control. (B) WiDr and HT-29 cells were treated with each nucleos(t)ide analogue (NUC) diluted 1:3 (maximum concentration of each NUC is shown above). (C) WiDr and HT-29 cells were treated under the same conditions as above for 24 hours, and total RNA was extracted. The IL-28B mRNA expression level was determined using real-time PCR, as described in the online supplementary materials and methods. At least three independent experiments were conducted in triplicate, and representative data are shown. (D) WiDr cells were treated with 0.1% DMSO, 50 μM LAM, 2.5 μM ADV, 0.25 μM ETV or 50 μM TDF for 48 hours, and immunohistochemistry was performed. ‘No Ab’ indicates that the cells were treated without the primary antibody. Arrowheads indicate positive staining. Scale bar represents 50 μm. *p<0.05, **p<0.01 and ***p<0.001. PC, positive controls.
ETV and TDF both similarly decrease the HBV DNA levels with low rates of antiviral drug resistance. However, HBsAg loss was achieved only in a small portion of patients on single-drug treatment. In other words, even if TDF provides the novel additional effect demonstrated in the current study, the effect from a single-drug treatment is not sufficient, and additional strategies are required for HBsAg loss. Type I and type III IFNs exhibit different kinetics of ISG induction. The ISG induction by type I IFNs is strong but transient, whereas type III IFNs cause less strong but more sustained ISG induction. Thus, co-administration of these two types of cytokines is expected to result in a complementary antiviral effect. In addition, IFN-α had an additive effect on IFN-λ3 production with nucleotide analogues in vitro (see online supplementary figure S9A and B). These enhanced IFN-λ3 levels together with IFN-α might further enhance ISG expression. Therefore, a combination of nucleotide analogues with PEG-IFN could theoretically be a promising treatment method. A direct comparison is difficult due to the differences in clinical background factors and treatment regimens, but actual simultaneous administration of PEG-IFN and ADV or TDF has resulted in a high probability of HBsAg loss, whereas co-administration of PEG-IFN and first-generation NUCs, especially LAM, has generated results similar to those obtained with PEG-IFN alone.

IFNL4 is associated with treatment-response in chronic hepatitis C as well as IL28B. A strong linkage disequilibrium between rs8099917 (IL28B) and rs368234815 (IFNL4) was reported in the Japanese population (rs2=0.94). In addition, functional IFN-λ4 is eliminated through pseudogenisation in most individuals of Japanese descent. Therefore, we did not
investigate IFNL4 and IFN-λ4 in this study. However, further studies are needed in the European and the African populations because the allele frequency of rs368234815 in the Japanese population was quite different from what was obtained in those populations as shown in the 1000 Genomes data set46 and the HapMap samples (see online supplementary table S2).

In conclusion, we discovered a novel additional pharmacological effect of orally administered nucleotide analogues, which were found to directly induce IFN-λ3 in GI cells. Consequently, IFN-λ3 causes the induction of ISGs, which in turn results in the inhibition of HBAg production in hepatic cells. This discovery may provide new insights into anti-HBV therapy and suggests the possibility of developing an anti-HBV therapy targeting IFN-λ3 induction.

Author affiliations
1 The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan
2 Department of Hepatitis and Immunology, Nagoya City University Graduate School of Medical Science, Nagoya, Japan
3 Department of Medicine, Shinshu University of Medicine, Matsumoto, Japan
4 First Department of Medicine, University of Yamashita, Chuo, Japan
5 Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
6 AIDs Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan
7 Department of Gastroenterology, The Research Center for Hepatitis and Immunology, Research Institute, National Center for Global Health and Medicine, Ichikawa, Japan
8 Division of Colorectal Surgery, Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan

Acknowledgements The authors thank Editage (http://www.editage.jp) for English language editing.

Contributors KM and MM conceived and designed the experiments. AM, ET, TI, MS, NE, MH, SK, HG, SO, YS and HY collected patient samples and performed the analyses. KM, MA, MS, NN, TS, MH, YIK and TD performed the experiments. KM and MM wrote the manuscript.

Funding This study was supported by the National Center for Global Health and Medicine in Japan (27-1302), Grants-in-Aid for Scientific Research (23390117), and Japan Agency for Medical Research and Development (15fk0210035h0001).

Competing interests None declared.

Patient consent Obtained.

Ethics approval Local Ethics Committee at each associated institute (reference number NCGM-A-000208-0).

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES